USD 0.13
(-0.15%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 | 12 Thousand USD | 0.0% |
2023 | 1.01 Million AUD | 30.65% |
2022 | 776.04 Thousand AUD | 4.79% |
2021 | 740.53 Thousand AUD | 597.4% |
2020 | 106.18 Thousand AUD | -82.19% |
2019 | 596.25 Thousand AUD | 22.15% |
2018 | 488.15 Thousand AUD | 308.21% |
2017 | -234.45 Thousand AUD | 0.0% |
2016 | - AUD | 0.0% |
2015 | - AUD | 0.0% |
2014 | - AUD | -100.0% |
2013 | 35.73 Thousand AUD | -46.12% |
2012 | 66.31 Thousand AUD | 0.0% |
2011 | - AUD | -100.0% |
2010 | 26.18 Thousand AUD | 0.0% |
2009 | - AUD | 0.0% |
2008 | - AUD | 0.0% |
2007 | - AUD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q4 | -50 Thousand USD | 0.0% |
2024 Q3 | -17 Thousand USD | 0.0% |
2024 Q2 | - USD | 0.0% |
2024 Q1 | - USD | -100.0% |
2023 Q3 | - USD | 0.0% |
2023 Q2 | - USD | 0.0% |
2023 Q1 | - USD | -100.0% |
2023 Q4 | 959.56 Thousand USD | 0.0% |
2023 FY | 1.01 Million AUD | 30.65% |
2022 FY | 776.04 Thousand AUD | 4.79% |
2022 Q4 | 614.42 Thousand USD | 0.0% |
2021 FY | 740.53 Thousand AUD | 597.4% |
2020 FY | 106.18 Thousand AUD | -82.19% |
2019 FY | 596.25 Thousand AUD | 22.15% |
2018 FY | 488.15 Thousand AUD | 308.21% |
2017 FY | -234.45 Thousand AUD | 0.0% |
2016 FY | - AUD | 0.0% |
2016 Q3 | - AUD | 0.0% |
2016 Q4 | - AUD | 0.0% |
2016 Q1 | - AUD | 0.0% |
2016 Q2 | - AUD | 0.0% |
2015 Q1 | - AUD | 0.0% |
2015 FY | - AUD | 0.0% |
2015 Q4 | - AUD | 0.0% |
2015 Q3 | - AUD | 0.0% |
2015 Q2 | - AUD | 0.0% |
2014 Q2 | 8933.75 AUD | 0.0% |
2014 FY | - AUD | -100.0% |
2014 Q3 | - AUD | -100.0% |
2014 Q4 | - AUD | 0.0% |
2014 Q1 | 8933.75 AUD | 0.0% |
2013 Q4 | 8933.75 AUD | 0.0% |
2013 Q1 | 16.57 Thousand AUD | 0.0% |
2013 Q2 | 16.57 Thousand AUD | 0.0% |
2013 FY | 35.73 Thousand AUD | -46.12% |
2013 Q3 | 8933.75 AUD | -46.11% |
2012 FY | 66.31 Thousand AUD | 0.0% |
2012 Q4 | 16.57 Thousand AUD | 0.0% |
2012 Q3 | 16.57 Thousand AUD | 0.0% |
2012 Q2 | - AUD | 0.0% |
2012 Q1 | - AUD | 0.0% |
2011 Q4 | - AUD | 0.0% |
2011 FY | - AUD | -100.0% |
2011 Q3 | - AUD | -100.0% |
2011 Q1 | 6545.25 AUD | 0.0% |
2011 Q2 | 6545.25 AUD | 0.0% |
2010 Q3 | 6545.25 AUD | 0.0% |
2010 Q4 | 6545.25 AUD | 0.0% |
2010 FY | 26.18 Thousand AUD | 0.0% |
2010 Q1 | - AUD | 0.0% |
2010 Q2 | - AUD | 0.0% |
2009 Q1 | - AUD | 0.0% |
2009 Q4 | - AUD | 0.0% |
2009 Q2 | - AUD | 0.0% |
2009 Q3 | - AUD | 0.0% |
2009 FY | - AUD | 0.0% |
2008 Q3 | - AUD | 0.0% |
2008 Q1 | - AUD | 0.0% |
2008 FY | - AUD | 0.0% |
2008 Q4 | - AUD | 0.0% |
2008 Q2 | - AUD | 0.0% |
2007 Q3 | - AUD | 0.0% |
2007 FY | - AUD | 0.0% |
2007 Q4 | - AUD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
Esperion Therapeutics, Inc. | 73.06 Million USD | 99.984% |
Theratechnologies Inc. | 62.12 Million USD | 99.981% |
Safety Shot Inc | -74.45 Thousand USD | 116.117% |
Cosmos Health Inc. | 4.34 Million USD | 99.724% |
Cronos Group Inc. | 6.99 Million USD | 99.828% |
Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | 99.997% |
Kala Pharmaceuticals, Inc. | -303 Thousand USD | 103.96% |
Organogenesis Holdings Inc. | 309.79 Million USD | 99.996% |
Universe Pharmaceuticals INC | 10.07 Million USD | 99.881% |
ProPhase Labs, Inc. | 16.23 Million USD | 99.926% |
Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | 99.747% |
Dynavax Technologies Corporation | 182.11 Million USD | 99.993% |
Radius Health, Inc. | 307.71 Million USD | 99.996% |
China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | 97.834% |
Alvotech | -69.42 Million USD | 100.017% |
Sunshine Biopharma, Inc. | 8.33 Million USD | 99.856% |
Alpha Teknova, Inc. | 10.29 Million USD | 99.883% |
Intra-Cellular Therapies, Inc. | 430.62 Million USD | 99.997% |
SCYNEXIS, Inc. | 124.51 Million USD | 99.99% |
Harrow Health, Inc. | 90.55 Million USD | 99.987% |
Biofrontera Inc. | 16.62 Million USD | 99.928% |
DURECT Corporation | 6.83 Million USD | 99.824% |
Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 99.998% |
ANI Pharmaceuticals, Inc. | 305.3 Million USD | 99.996% |
OptiNose, Inc. | 62.35 Million USD | 99.981% |
RedHill Biopharma Ltd. | 3.05 Million USD | 99.607% |
Aquestive Therapeutics, Inc. | 29.75 Million USD | 99.96% |
Cumberland Pharmaceuticals Inc. | 33.48 Million USD | 99.964% |
SIGA Technologies, Inc. | 122.09 Million USD | 99.99% |
Lifecore Biomedical, Inc. | 41.85 Million USD | 99.971% |
Shineco, Inc. | 882.16 Thousand USD | 98.64% |
Phibro Animal Health Corporation | 312.48 Million USD | 99.996% |
Procaps Group S.A. | 239.56 Million USD | 99.995% |
TherapeuticsMD, Inc. | 1.3 Million USD | 99.078% |
Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 101.609% |
Viatris Inc. | 6.43 Billion USD | 100.0% |
Sunshine Biopharma, Inc. | 8.33 Million USD | 99.856% |
Rockwell Medical, Inc. | 8.7 Million USD | 99.862% |
Aytu BioPharma, Inc. | 54.58 Million USD | 99.978% |
Tilray Brands, Inc. | 223.35 Million USD | 99.995% |
Collegium Pharmaceutical, Inc. | 326.16 Million USD | 99.996% |
PetIQ, Inc. | 252.74 Million USD | 99.995% |
Silver Spike Investment Corp. | 8.1 Million USD | 99.852% |
Neurocrine Biosciences, Inc. | 1.84 Billion USD | 99.999% |
Journey Medical Corporation | 52.52 Million USD | 99.977% |
Alimera Sciences, Inc. | 61.17 Million USD | 99.98% |
Petros Pharmaceuticals, Inc. | 4.19 Million USD | 99.714% |
Assertio Holdings, Inc. | 125.04 Million USD | 99.99% |
Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 276.186% |
Embecta Corp. | 749.9 Million USD | 99.998% |
Cyclo Therapeutics, Inc. | -2.41 Million USD | 100.498% |
Procaps Group, S.A. | 239.56 Million USD | 99.995% |
PainReform Ltd. | -15 Thousand USD | 180.0% |
Avadel Pharmaceuticals plc | 27.11 Million USD | 99.956% |
Hempacco Co., Inc. | -1.21 Million USD | 100.987% |
Talphera, Inc. | -4.89 Million USD | 100.245% |
Pacira BioSciences, Inc. | 490.3 Million USD | 99.998% |
Alvotech | -69.42 Million USD | 100.017% |
Lantheus Holdings, Inc. | 709.54 Million USD | 99.998% |
Kamada Ltd. | 52.59 Million USD | 99.977% |
Indivior PLC | 907 Million USD | 99.999% |
Currenc Group, Inc. | 17.35 Million USD | 99.931% |
Evoke Pharma, Inc. | 4.97 Million USD | 99.759% |
Flora Growth Corp. | 17.73 Million USD | 99.932% |
Cyclo Therapeutics, Inc. | -2.41 Million USD | 100.498% |
Evolus, Inc. | 140.52 Million USD | 99.991% |
HUTCHMED (China) Limited | 453.55 Million USD | 99.997% |
Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | 99.997% |
Akanda Corp. | 111.44 Thousand USD | 89.233% |